Brian Goff, Agios CEO
June 26, 2023 11:13 AM EDTUpdated 11:38 AM
R&D

Look­ing to ex­pand Pyrukynd la­bel, Agios treks to­ward PhI­II in sick­le cell dis­ease

Lei Lei Wu

News Reporter

Agios Phar­ma­ceu­ti­cals said Mon­day that its pill Pyrukynd in­creased lev­els of he­mo­glo­bin in more sick­le cell dis­ease pa­tients than place­bo, and it plans to start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times